Previous 10 | Next 10 |
2023-04-11 12:13:33 ET Shares of Adaptimmune Therapeutics (NASDAQ: ADAP) were up as much as 9.7% early Tuesday after the clinical-stage biotech announced that it had reached an agreement with GSK (NYSE: GSK) to return the rights to Adaptimmune's PRAME and NY-ESO cell therapy...
2023-04-11 09:35:58 ET Adaptimmune Therapeutics ( NASDAQ: ADAP ) said it will regain rights to the PRAME and NY-ESO cell therapy programs from GSK ( NYSE: GSK ). Adaptimmune will receive an upfront payment plus milestone-based payments totaling £30M related t...
- Adaptimmune plans to be IND-ready in 2023 with a PRAME targeted TCR T-cell therapy - - Adaptimmune and GSK will work collaboratively to ensure continuity for patients in ongoing clinical trials for lete-cel and next generation TCR T-cells targeting NY-ESO - -Adaptimmune will receive £30 ...
NEW YORK, NY / ACCESSWIRE / April 2, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Radius Global Infrastructure, Inc....
2023-03-26 07:12:58 ET Summary ADAP is down after merging with TCRR, while TCRR is up. The merger dilutes ADAP, but in return, it gets one year of additional cash and the TCRR pipeline for free. The merger looks like a smart deal for ADAP. For further det...
2023-03-06 15:40:06 ET Adaptimmune Therapeutics plc (ADAP) Q4 2022 Earnings Conference Call March 06, 2023, 08:00 AM ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief Executive Officer Garry Menzel - President and Chief Execut...
2023-03-06 13:05:55 ET Gainers: Bellerophon ( BLPH ) +86% . Ambrx Biopharma ( AMAM ) +69% . BridgeBio Pharma ( BBIO ) +56% . Avalon GloboCare ( ALBT ) +47% . Azul ( AZUL ) +42% . TCR2 Therapeutics ( TCRR ) +38% . ...
2023-03-06 10:00:19 ET Gainers: BridgeBio Pharma ( BBIO ) +67% . Armata Pharmaceuticals ( ARMP ) +23% . TCR2 Therapeutics ( TCRR ) +21% . Euda Health ( EUDA ) +12% . Kala Pharmaceuticals ( KALA ) +16% . Losers: Aclaris...
2023-03-06 08:17:23 ET Aclaris Therapeutics ( ACRS ) -38% after preliminary topline data from 12-week Phase 2a study did not meet primary or secondary efficacy endpoints in hidradenitis suppurativa . Esperion Therapeutics ( ESPR ) -27% amid Nexletol data ...
2023-03-06 07:27:05 ET Shares of Adaptimmune Therapeutics ( NASDAQ: ADAP ) are down 26% premarket despite Q4 earnings beat after the company announced a strategic agreement with TCR² Therapeutics . Both the companies will combine in an all-stock transactio...
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
2024-07-30 07:30:03 ET H.C. Wainwright analyst issues BUY recommendation for ADAP on July 30, 2024 06:07AM ET. ADAP was trading at $1.37 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy, 1 - Hold, ...
2024-07-30 07:00:10 ET Arthur He from H.C. Wainwright issued a price target of $4.00 for ADAP on 2024-07-30 06:07:00. The adjusted price target was set to $4.00. At the time of the announcement, ADAP was trading at $1.37. The overall price target consensus is at $2.54 wi...